D-0983-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0983-2017 was initiated by Teva Pharmaceuticals USA on Jun 29, 2017 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity. The recall status is terminated (terminated Apr 26, 2018). Affected quantity: 25264 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 26, 2017
Initiation Date
Jun 29, 2017
Termination Date
Apr 26, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
25264 bottles

Product description

Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg 30 tablets per bottle, Rx only, Distributed by: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5720-56

Reason for recall

Failed Impurities/Degradation Specifications: out of specification test results for related compounds largest unknown impurity.

Distribution pattern

Nationwide in the USA

Code information

Lot #: 30227613A, 30227614A, 30227615A, EXP 6/2017; 30228559A, 30228560A, EXP 9/2017; 3000123, EXP 7/2018

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0983-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0983-2017. Report a data issue: hello@regdatalab.com.